KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803

PURPOSE: Alterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-EGFR targeted therapy (cetuximab or panitumumab). However, it remains uncertain w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ogino, Shuji, Meyerhardt, Jeffrey A., Irahara, Natsumi, Niedzwiecki, Donna, Hollis, Donna, Saltz, Leonard B., Mayer, Robert J., Schaefer, Paul, Whittom, Renaud, Hantel, Alexander, Benson, Al B., Goldberg, Richard M., Bertagnolli, Monica M., Fuchs, Charles S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2787689/
https://ncbi.nlm.nih.gov/pubmed/19934290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1570
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi